Literature DB >> 15197330

Hypoxic gene expression and metastasis.

Quynh-Thu Le1, Nicholas C Denko, Amato J Giaccia.   

Abstract

Solid tumors possess malformed vasculature that results in the exposure of tumor cells to a low oxygen environment. Tumor hypoxia has been demonstrated in human and mouse tumors through the use of oxygen microelectrodes, hypoxic specific biomarkers, specific transcriptional changes induced by hypoxia, and secreted proteins. While many elegant experiments have demonstrated that hypoxia enhances metastatic potential, it is still unknown what mechanisms are involved in this enhancement. In this review, we discuss the clinical and basic science studies that support an important role for hypoxia in increasing the metastatic potential of tumor cells by promoting tissue remodeling, inducing angiogenesis and reducing apoptosis. Particular emphasis is given to recent findings that provide insight to the role of hypoxia in the metastatic process.

Entities:  

Mesh:

Year:  2004        PMID: 15197330     DOI: 10.1023/B:CANC.0000031768.89246.d7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  77 in total

1.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

2.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Authors:  Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Sara Rockwell; Alan C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

Review 3.  Effects of hypoxia on heterotypic macrophage interactions.

Authors:  Benjamin T Spike; Kay F Macleod
Journal:  Cell Cycle       Date:  2007-08-13       Impact factor: 4.534

4.  Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.

Authors:  Raymond P Baumann; Philip G Penketh; Kimiko Ishiguro; Krishnamurthy Shyam; Yong L Zhu; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

5.  Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells.

Authors:  Raymond P Baumann; Philip G Penketh; Helen A Seow; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Radiat Res       Date:  2008-11       Impact factor: 2.841

Review 6.  Three-dimensional context regulation of metastasis.

Authors:  Janine T Erler; Valerie M Weaver
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

7.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Authors:  Priya Prakash Karmali; Venkata Ramana Kotamraju; Mark Kastantin; Matthew Black; Dimitris Missirlis; Matthew Tirrell; Erkki Ruoslahti
Journal:  Nanomedicine       Date:  2008-10-01       Impact factor: 5.307

9.  Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

Authors:  Laura M S Seeber; Ronald P Zweemer; René H M Verheijen; Paul J van Diest
Journal:  Obstet Gynecol Int       Date:  2010-02-14

10.  Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.

Authors:  Laura M S Seeber; Nicole Horrée; Petra van der Groep; Elsken van der Wall; René H M Verheijen; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-06-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.